Mr. Andre Larente reports

DIAGNOS ANNOUNCES STOCK OPTIONS GRANTS

Diagnos Inc. has granted a total of 125,000 stock options to two of its officers. Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The exercise price of these stock options has been established at 57 cents per share. The expiry date to which these stock options can be exercised has been fixed to March 2, 2026.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based off its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the U.S. Food and Drug Administration (United States), CE (Europe), COFEPRIS (Mexico), and the Saudi Food and Drug Authority (Saudi Arabia).

We seek Safe Harbor.